Meet the Team

The Glo-BNHL trial is co-ordinated by the Children’s Cancer Trials B Team (CCTT-B) based within the Cancer Research UK Clinical Trials Unit (CRCTU) at the University of Birmingham.

 

Professor Amos Burke

Professor Amos Burke, Chief Investigator

Professor Lucinda Billingham

Professor Lucinda Billingham, Chief Biostatistician

Emma Seaford

Dr Emma Seaford Lead, Early Career Investigator

Anna Lawson_HeadshotAnna Lawson, Trial Management Team Leader
Rebecca BishopRebecca Bishop, Industry Trials Hub Lead
Akshay DeshpandeDr Akshay Deshpande, Clinical Research Fellow
Joe RogersJoseph Rogers, Senior Trial Coordinator 
Sarah JohnsonSarah Johnson, Senior Trial Coordinator
Rhi ParsonsRhianna Parsons, Project Manager
Shanna MaycockShanna Maycock, Senior Biostatistician
Jiayi WangJiayi Wang, Trial Statistician
Mahnoor MuzaffarMahnoor Muzaffar, Trial Coordinator
Zahra AhmedZahra Ahmed, Trial Coordinator
Faiza Suleman
Faiza Suleman, Trial Administrator

 

  

Treatment Arm Leads contribute to the Glo-BNHL trial by acting as deputies for the Chief Investigator for a specific treatment arm. There are two Co-lead Investigators for each arm, and two Early Career Investigators in each arm to support them.

Treatment Arm I: Odronextamab (Bispecific antibody), Regeneron Pharmaceuticals Inc.

  • Treatment Arm Co-lead - Simon Bomken
  • Treatment Arm Co-lead - Sarah Alexander
  • Early Career Investigator - Charlotte Rigaud
  • Early Career Investigator - Charles Phillips

Treatment Arm II: Loncastuximab tesirine (Antibody Drug Conjugate) with standard chemotherapy, ADC Therapeutics SA

  • Treatment Arm Co-lead - Auke Beishuizen
  • Treatment Arm Co-lead - Birte Wistinghausen
  • Early Career Investigator - Emma Seaford
  • Early Career Investigator - James Ford

Treatment Arm III: Chimeric antigen receptor (CAR) T-cells, TBC

  • Treatment Arm Co-lead - Veronique Minard-Colin
  • Treatment Arm Co-lead - Joerg Krueger
  • Early Career Investigator - Friederike Meyer-Wentrup
  • Early Career Investigator - Keri Toner

Treatment Arm IV: Golcadomide (CELMoD™ agent) with Rituximab, Bristol Myers Squibb

  • Treatment Arm Co-lead - Veronique Minard-Colin
  • Treatment Arm Co-lead - Nader El-Mallawany
  • Early Career Investigator - Kaitlin Devine
  • Early Career Investigator - Akshay Deshpande

Trial Management Group

The Trial Management Group (TMG) is a group of professionals from many different fields and organisations. The TMG meets several times a year to assist with the overall management of the trial and to make important trial related decisions.

  • Amos Burke - Chief Investigator
  • Lucinda Billingham - Lead Biostatistician
  • Trial Management Team Representatives
  • Shanna Maycock - Senior Biostatistician
  • Jiayi Wang - Statistician
  • Nicole Scobie - Patient Advocate
  • Dave Hulme - Patient Advocate
  • Suzanne Turner - Biology Lead
  • Sarah Alexander - Treatment Arm Co-lead
  • Simon Bomken - Treatment Arm Co-lead
  • Auke Beishuizen - Treatment Arm Co-lead
  • Birte Wistinghausen - Treatment Arm Co-lead
  • Véronique Minard - Treatment Arm Co-lead
  • Joerg Kruger - Treatment Arm Co-lead
  • Charlotte Rigaud - Early Career Investigator
  • Charles Phillips - Early Career Investigator
  • Emma Seaford - Lead Early Career Investigator
  • James Ford - Early Career Investigator
  • Friederike Meyer-Wenthrup - Early Career Investigator
  • Keri Toner - Early Career Investigator
  • Nader El Mallawany - Treatment Arm Co-lead
  • Kaitlin Devine - Early Career Investigator
  • Amelie Alfert - Early Career Investigator
  • Anthony Audino - Treatment Arm Co-lead
  • National Coordinating Centre Representatives

Trial Steering Committee

The international Trial Steering Committee (TSC) is a group of independent professionals, whose role is to provide overall supervision for the trial on behalf of the Trial Sponsor (University of Birmingham) and the Trial Funders (Cancer Research UK and Fight Kids Cancer). They make sure that the trial is performed in line with the high standards of International Conference on Harmonisation Good Clinical Practice (ICH-GCP), most importantly focusing on the safety and well-being of the children, adolescents and young people involved.

  • Lia Gore - Independent Chair
  • Amos Burke - Chief Investigator
  • Emma Seaford - Lead Early Career Researcher
  • Sarah Alexander - Treatment Arm Co-lead
  • Carl Allen - Professor of Paediatric Oncology
  • Auke Beishuizen - Treatment Arm Co-lead
  • Josef Vormoor - Professor of Paediatric Oncology
  • Lucinda Billingham - Lead Biostatistician
  • Shanna Maycock - Senior Biostatistician
  • Anne Auperin - Independent Statistician
  • Catherine Bollard - Professor of Paediatrics
  • Victoria Buenger - Patient Advocate
  • Willemijn Plieger-van Solkema - Patient Advocate
  • Véronique Minard - Treatment Arm Co-lead
  • Birte Wistinghausen - Treatment Arm Co-lead
  • Trial Management Team Representatives